sponsored
PatientsVille.com Logo

PatientsVille

Daunorubicin Medical Research Studies

Up-to-date List of Daunorubicin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Daunorubicin Medical Research Studies

Rank Status Study
1 Recruiting Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML
Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: study part 1 - dose Daunorubicin;   Procedure: induction cycles
Outcome Measures: response rate after first induction;   Rate complete remissions;   rate cytogenetic and molecular complete remissions;   event-free survival (EFS);   relapse-free survival (RFS);   overall survival (OS);   Correlation between Minimal Residual Disease (MRD) and EFS, RFS, OS;   Rate of induction deaths;   Incidence of serious infectious complications;   Sonographic cardiac left ventricular ejection fraction;   Serum levels of pro-brain natriuretic peptide (por-BNP) and Troponin-T;   Incidence of CTCAE grade ≥3 cardiac complications;   Rate of early deaths
2 Recruiting Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Daunorubicin hydrochloride;   Drug: cytarabine;   Drug: nilotinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Proportion of complete responses (CR or CRi) during induction therapy;   Overall survival (OS);   OS rate;   Disease-free survival time (DFS);   DFS rate;   Duration of complete response;   Incidence of adverse events as assessed by NCI CTCAE version 4.0
3 Recruiting Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Conditions: Acute Myeloid Leukemia;   Advanced Myelodysplastic Syndrome
Interventions: Drug: Panobinostat;   Drug: Cytarabine;   Drug: Daunorubicin
Outcome Measures: The maximum tolerated dose (MTD) for the combination of panobinostat with standard-dose cytarabine and Daunorubicin (7+3) for untreated AML and advanced MDS in the elderly.;   The recommended Phase II dose for the combination of panobinostat with standard-dose cytarabine and Daunorubicin (7+3) for untreated AML and advanced MDS in the elderly.;   Response rate (OR, CR, CRi) for AML using Revised Recommendations of the International Working Group;   Response rate (OR, CR, CRi) for AMS using International Working Group response criteria in myelodysplasia;   Relapse-free survival;   Overall Survival
4 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine;   Drug: Daunorubicin hydrochloride;   Drug: idarubicin;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: EFS;   Rate of allogeneic HCT;   EFS of 7 + 3 compared to IA;   EFS rate;   OS rate
5 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: Daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Outcome Measures: Overall survival;   Mortality rate;   Induction complete response rates;   Disease-free survival (DFS);   Epidemiological factors, measured using the Acute Leukemia Epidemiology and Survival in ECOG (ALESE) questionnaire;   Change in the Functional Assessment of Cancer Therapy (FACT)-Leukemia-specific (Leu) Trial Outcome Index (TOI) score;   Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score
6 Recruiting Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myelomonocytic Leukemia (M4);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Daunorubicin hydrochloride;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Complete remission rate (CR1);   Complete remission rate (CR1 + CR2);   Overall survival;   Relapse-free survival;   Event-free survival;   Time to complete response determined according to the International Working Group (IWG) criterion;   Remission duration
7 Recruiting Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: OMEGAVEN;   Drug: Daunorubicin;   Drug: Cytarabine
Outcome Measures: response to study treatment;   Tolerance;   Efficacy on peripheral blasts decrease;   pharmacokinetics
8 Recruiting Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: liposomal cytarabine-Daunorubicin CPX-351;   Other: laboratory biomarker analysis
Outcome Measures: Response (CR or CRp) rate categorized according to criteria recommended by International Working Groups;   TRM rate
9 Recruiting Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine;   Drug: Daunorubicin hydrochloride;   Drug: etoposide;   Drug: pomalidomide;   Other: laboratory biomarker analysis
Outcome Measures: MTD of pomalidomide, defined as the highest dose at which 0 or 1 dose-limiting toxicities (DLT) are observed in 6 patients according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0;   Proportion of toxicities in the expansion cohort graded according to NCI CTCAE version 4.0;   Proportion of patients achieving CR, CRi, or PR;   Progression-free survival (PFS);   Overall survival
10 Unknown  Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: clofarabine;   Drug: cytarabine;   Drug: Daunorubicin hydrochloride;   Drug: decitabine;   Other: clinical observation
Outcome Measures: Overall survival;   30-day mortality rate;   Induction complete response rates;   Effect of decitabine as maintenance therapy vs observation on disease-free survival;   Impact of consolidation therapy with non-myeloablative conditioning and allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donor on overall survival in select patients;   Quality of life
11 Unknown  Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: cytarabine;   Drug: Daunorubicin hydrochloride;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Maximum tolerated dose of everolimus;   Toxicity;   Activation of PI3K/AKT and mTORC 1 in leukemic blasts;   Pharmacokinetics of everolimus
12 Unknown  Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Cytarabine plus Daunorubicin [Arm II (AD regimen)]
Outcome Measures: Complete remission rate;   Duration of CR, relapse-free survival(RFS),event-free survival(EFS),Overall survival(OS)
13 Recruiting Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351;   Drug: 7+3 (cytarabine and Daunorubicin)
Outcome Measure: Overall Survival
14 Recruiting Clofarabine or High-Dose Cytarabine, Pegaspargase, and Combination Chemotherapy Followed by Daunorubicin Hydrochloride or Doxorubicin Hydrochloride in Treating Young Patients With Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: amsacrine;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: Daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Outcome Measures: Safety and efficacy of clofarabine combined with pegaspargase (phase II);   Cytotoxic efficacy of clofarabine compared with high-dose (HD) cytarabine in combination with pegaspargase (phase III);   Incidence of infectious complications after administration of Daunorubicin hydrochloride vs doxorubicin hydrochloride;   Safety profiles of clofarabine and pegaspargase vs HD cytarabine and pegaspargase;   Efficacy of clofarabine and pegaspargase and HD cytarabine and pegaspargase, in terms of minimal-residual disease (MRD) vs methotrexate, cyclophosphamide, and asparaginase in study COALL-07-03;   Impact of MRD-based stratification in COALL-09 on overall survival and event-free survival in a historical comparison of previous COALL studies
15 Recruiting A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Condition: Leukaemia, Acute
Interventions: Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Eltrombopag;   Drug: Placebo
Outcome Measures: Number of subjects with adverse events (AE) as a measure of safety and tolerability;   Change from baseline in the left ventricular ejection fraction (LVEF).;   Clinical laboratory assessment as measure of safety and tolerability.;   The number of platelet transfusions;   Time to platelet counts >=20 (Giga units per liter) Gi/L and >=100 Gi/L;   Proportion of subjects who achieve platelet count recovery by Day 21;   Summary of platelet counts;   Duration of platelet transfusion independence;   Time to absolute neutrophil count (ANC) engraftment defined as ANC recovery 0.5 Gi/L sustained for 3 days.;   Number of bleeding events;   Overall survival;   Off-treatment Medical resource utilization (MRU).;   Composite of pharmacokinetic (PK) parameters of Daunorubicin and Daunorubicinol on Cycle 1 Day 3.;   Composite of PK parameters of Daunorubicin and Daunorubicinol on Cycle 2 Day 1;   Changes in absolute neutrophil counts;   Changes in hemoglobin
16 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Interventions: Drug: decitabine;   Drug: azacitidine;   Drug: cytarabine;   Drug: idarubicin;   Drug: Daunorubicin hydrochloride;   Procedure: quality-of-life assessment
Outcome Measures: Failure-free survival (failure defined as death, lack of response to initial therapy, relapse after response to initial therapy);   Frequency at which the patients undergo transplantation;   Factors present at enrollment that predict transplant frequency;   Reasons for which patients were not transplanted;   Changes in quality of life scores using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30);   Change in comorbidities;   Overall Survival;   Relapse;   Relapse-free survival;   Incidence of acute and chronic GVHD assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
17 Recruiting Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: asparaginase;   Drug: Daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Event-free survival of MLL-R infants randomized to a modified P9407 backbone with or without lestaurtinib;   Safe, tolerable, and biologically active dose of lestaurtinib as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Pharmacokinetic profile of lestaurtinib by plasma inhibitory activity (PIA) assay
18 Not yet recruiting Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin
Outcome Measures: complete remission rate;   WT1 and MDR1 expression level change after 2 courses of chemotherapy with IA regimen or DA regimen in high-MDR1 expression AML patients.
19 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: Daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Outcome Measures: Event-free survival;   Overall survival;   Remission rate after 1 course of therapy;   Remission rate after 2 courses of therapy;   Proportion of patients dying in each course of therapy;   Course duration;   Length of hospitalization;   Time to blood count recovery;   Relapse rate assessed by bone marrow analsysis for leukemic blasts;   Incidence of treatment-related mortality;   Proportion of patients expereincing grade 3 or higher non-hematologic toxicities and infections assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0);   Proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II;   Parent-reported questionnaire scores;   Change in parent-reported outcomes over time in recipients of SCT or chemotherapy;   Bortezomib pharmacokinetic plasma concentration-time profiles;   Systemic exposure of sorafenib and N-oxide metabolite for each course of induction and intensification (CL, Vd, time to maximum concentration [Tmax]½, area under curve [AUC]);   Shortening fraction/ejection fraction percentages and change over time;   Serum concentrations of GVHD biomarkers
20 Recruiting CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: liposomal cytarabine-Daunorubicin CPX-351;   Other: laboratory biomarker analysis
Outcome Measures: Incidence of mortality assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Incidence of mortality assessed using the CTCAE version 4.0;   Incidence of serious adverse events as assessed by CTCAE version 4.0;   Frequency of grade 3-5 adverse events as assessed by CTCAE version 4.0;   Response rate (CR + CRi) following induction therapy using the European Leukemia Net classification for AML and the International Working Group guidelines for MDS;   Duration of remission following induction with CPX-351;   Overall survival;   Early induction mortality after first induction

These studies may lead to new treatments and are adding insight into Daunorubicin etiology and treatment.

A major focus of Daunorubicin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Daunorubicin